At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
1 article- FDA assembles vaccine experts to update COVID-19 formulationBioSpace FDA·2026-05-27
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Antibody Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnant Woman and Transplacental Passage Into Cord Blood.
In Brief
A clinical study evaluating COVID-19 Spike Protein IgG Quantitative Antibody (CMIA) for Covid-19. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The goal of this study is to study the correlation of maternal and cord blood level of Anti SAR-CoV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesThailand
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartOct 2023
Primary CompletionNov 2023
First PostedFeb 2024
TodayJul 2026
First PostedFeb 14, 2024
Enrollment StartOct 25, 2023
Primary CompletionNov 25, 2023
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.4 years ago
Interventions
COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)other
Maternal blood and cord blood were collected to test for COVID-19 Spike Protein IgG Quantitative Antibody (CMIA)